A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Alba A. Brandes,Alicia Tosoni,Enrico Franceschi,V. Blatt,Armando Santoro,Marina Faedi,P. Amista,M. Gardiman,R. Labianca,C. Bianchini,Mario Ermani,Michele Reni +11 more
TL;DR: This is the first study to evaluate correlation between MGMT promoter status and outcome of fotemustine for relapsing GBM previously treated with radiotherapy and temozolomide and may represent a new benchmark for nitrosourea activity.
Journal ArticleDOI
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Janice M. Mehnert,Emily K. Bergsland,Bert H. O'Neil,Armando Santoro,Jan H.M. Schellens,Jan H.M. Schellens,Roger B. Cohen,Toshihiko Doi,Patrick A. Ott,Michael J. Pishvaian,Igor Puzanov,Kyaw L. Aung,Chiun Hsu,Christophe Le Tourneau,Christophe Le Tourneau,Christophe Le Tourneau,Antoine Hollebecque,Elena Elez,Kenji Tamura,M. Gould,Ping Yang,Karen Stein,Sarina Anne Piha-Paul +22 more
TL;DR: This multicohort, phase 1 KEYNOTE‐028 study evaluated the activity and safety of the anti–programmed cell death protein 1 immunotherapy pembrolizumab in patients with well-differentiated or moderately‐differentiated NETs.
Journal ArticleDOI
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
Armando Santoro,Vittorio Gebbia,T. Pressiani,Antonio Testa,Nicola Personeni,E. Arrivas Bajardi,Paolo Foa,Angela Buonadonna,Katia Bencardino,C. Barone,Daris Ferrari,A. Zaniboni,Maria Chiara Tronconi,Giacomo Cartenì,Michele Milella,Alessandro Comandone,S. Ferrari,Lorenza Rimassa +17 more
TL;DR: Vandetanib treatment did not improve PFS in patients with advanced biliary tract cancers and the safety profile of vandETanib did not show any additional AEs or worsening of already known AEs.
Journal ArticleDOI
Advances in the biology of malignant pleural mesothelioma.
Paolo Andrea Zucali,Giovanni Luca Ceresoli,F. De Vincenzo,Matteo Simonelli,Elena Lorenzi,Letizia Gianoncelli,Armando Santoro +6 more
TL;DR: Advances in the molecular biology of malignant pleural mesothelioma are reviewed in terms of pathogenesis, the major molecular pathways and the associated therapeutic strategies, and the roles of biomarkers.
Journal Article
Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Monica Balzarotti,Salvatore Grisanti,K. Granzow,A. Saladini,A. Sala,A Nozza,Alfredo Molteni,Francesco Passamonti,Carmelo Carlo-Stella,Armando Santoro,Salvatore Siena +10 more
TL;DR: Amifostine selectively protects human CFU-GM progenitor cells from the cytotoxicities of active metabolites of cyclophosphamide without altering its cytot toxic effect on malignant cells, as demonstrated in patients with breast cancer, malignant lymphomas, and acute leukemia.